Names | |
---|---|
IUPAC name
α-Hydro-ω-{[4-oxo-4-({(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl}oxy)butanoyl]oxy}poly(oxyethylene)
| |
Other names
Tocofersolan; Vitamin E PEG succinate; α-Tocopherol polyethylene glycol succinate (TPGS); Liqui-E
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.123.651 |
EC Number |
|
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
(C2H4O)nC33H54O5 | |
Molar mass | Variable |
Pharmacology | |
A11HA08 ( WHO) | |
License data | |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Clinical data | |
---|---|
Trade names | Vedrop |
Other names | Tocophersolan ( USAN US) |
AHFS/ Drugs.com | UK Drug Information |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
KEGG | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.123.651 |
Tocofersolan ( INN) or tocophersolan, also referred to as TPGS (for tocopherol polyethylene glycol succinate), is a synthetic water-soluble version of vitamin E. Natural forms of vitamin E are fat soluble, but not water-soluble. Tocofersolan is polyethylene glycol derivative of α-tocopherol that enables water solubility.
Tocofersolan is used as a vitamin E supplement or to treat vitamin E deficiency in individuals who cannot absorb fats due to disease. [3] On 24 July 2009 the European Medicines Agency approved tocofersolan under the trade name Vedrop 50 mg/ml oral solution for the treatment of vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age (depending on the region). [4]
Tocofersolan is also used in cosmetics and pharmaceuticals as an antioxidant. [5]
Names | |
---|---|
IUPAC name
α-Hydro-ω-{[4-oxo-4-({(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl}oxy)butanoyl]oxy}poly(oxyethylene)
| |
Other names
Tocofersolan; Vitamin E PEG succinate; α-Tocopherol polyethylene glycol succinate (TPGS); Liqui-E
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.123.651 |
EC Number |
|
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
(C2H4O)nC33H54O5 | |
Molar mass | Variable |
Pharmacology | |
A11HA08 ( WHO) | |
License data | |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Clinical data | |
---|---|
Trade names | Vedrop |
Other names | Tocophersolan ( USAN US) |
AHFS/ Drugs.com | UK Drug Information |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
KEGG | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.123.651 |
Tocofersolan ( INN) or tocophersolan, also referred to as TPGS (for tocopherol polyethylene glycol succinate), is a synthetic water-soluble version of vitamin E. Natural forms of vitamin E are fat soluble, but not water-soluble. Tocofersolan is polyethylene glycol derivative of α-tocopherol that enables water solubility.
Tocofersolan is used as a vitamin E supplement or to treat vitamin E deficiency in individuals who cannot absorb fats due to disease. [3] On 24 July 2009 the European Medicines Agency approved tocofersolan under the trade name Vedrop 50 mg/ml oral solution for the treatment of vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age (depending on the region). [4]
Tocofersolan is also used in cosmetics and pharmaceuticals as an antioxidant. [5]